Embedding Continuous Improvement Initiatives Across Group Companies
First written in FY2018. 7 of 8 entries say "Restated". Latest entry: FY2020.
0 other companies' latest entry also says "Restated".
- FY2020RestatedAnnual report
「In the Medical Supply business, performance progressed steadily as we worked to acquire new projects, particularly in specialty materials, and improve the operating efficiency of SPD facilities.」
The policy of improving performance through continuous improvement activities, including acquiring new projects, collaboration across Group companies and greater operating efficiency at SPD facilities, is being reaffirmed. - FY2020-Q3RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by small-scale M&A and ongoing operating-efficiency improvement measures, among other factors. As a result, revenue was ¥20,285 million, up 6.3% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥1,946 million, up 25.5%.」
Small-scale M&A and the implementation of continuous operating-efficiency measures were reaffirmed, and segment profit in the dispensing pharmacy business increased 25.5% year on year. - FY2020-Q2RestatedAnnual report
「The Medical Supply business performed steadily through collaboration with the Total Pack Produce business, the acquisition of contracts for new SPD facilities, and more efficient operation of SPD facilities. There was also front-loaded demand for consumables ahead of the consumption tax increase. As a result, revenue was ¥160,607 million, up 16.8% from the cumulative second quarter of the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,455 million, up 43.3%.」
It is explained that continued collaboration across Group companies and greater efficiency in operating SPD facilities led to increases in revenue and segment profit in the Medical Supply business. - FY2020-Q1RestatedAnnual report
「In the Medical Supply business, securing profits remains difficult due to the impact of last year's reimbursement price revisions. However, performance was broadly in line with the plan through collaboration within the Group and greater operating efficiency.」
The policy of continuing improvements through collaboration within the Group and greater operating efficiency is being reaffirmed. - FY2019-Q3RestatedAnnual report
「In the dispensing pharmacy business, the number of stores increased through new store openings and small-scale M&A, while ongoing operating improvements were implemented. However, performance remained challenging because of the impact of revised dispensing fees.」
The policy of continuing operational improvements alongside new store openings and small-scale M&A is being reaffirmed, but challenging conditions continue due to the impact of the dispensing fee revision. - FY2019-Q2RestatedAnnual report
「In the dispensing pharmacy business, we implemented plans to open new stores and continuous measures to improve operating efficiency, but conditions remained challenging due to the impact of the dispensing fee revision.」
The policy of implementing continuous measures to improve operating efficiency is being reaffirmed, but conditions remained challenging during the quarter due to the impact of the dispensing fee revision. - FY2019-Q1RestatedAnnual report
「In the dispensing pharmacy business, continuous measures to improve operating efficiency were implemented, but performance remained weak due to the impact of the revision to dispensing fees.」
The policy of continuously improving operating efficiency in the dispensing pharmacy business is being reaffirmed, but the impact of the dispensing fee revision outweighed it, and performance remained weak during the quarter. - FY2018First statedAnnual report
「Continuous kaizen activities have taken root across Group companies and are producing results, while」
An initiative to embed continuous improvement activities across Group companies and link them to improved performance is being explicitly stated for the first time.